Tags

Type your tag names separated by a space and hit enter

Injectable and implantable contraceptives.
Curr Opin Obstet Gynecol. 1992 Aug; 4(4):536-43.CO

Abstract

In December 1990, the Food and Drug Administration approved Norplant (Wyeth-Ayerst, Radnor, PA) for general US use. This approval comes during a time period when the number of contraceptors relying on sterilization has risen, echoing known dissatisfaction with other reversible methods. During the past year, data have been presented that refute concern that Norplant may be an abortifacient. Continued estradiol production with development of follicles and ovulation in regularly menstruating women was documented. Ovulatory dysfunction among Norplant users, despite follicular development, was also detailed. Changes in carbohydrate metabolism were confirmed to be clinically insignificant. International development of biodegradable and non-biodegradable implants and 1, 3, or 6 months injectables continues. These injectable and implantable contraceptives promise diversity in contraceptive options to match diversity in contraceptive need and life style.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Francis Scott Key Medical Center, Baltimore, MD 21224.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1387011

Citation

Cullins, V E.. "Injectable and Implantable Contraceptives." Current Opinion in Obstetrics & Gynecology, vol. 4, no. 4, 1992, pp. 536-43.
Cullins VE. Injectable and implantable contraceptives. Curr Opin Obstet Gynecol. 1992;4(4):536-43.
Cullins, V. E. (1992). Injectable and implantable contraceptives. Current Opinion in Obstetrics & Gynecology, 4(4), 536-43.
Cullins VE. Injectable and Implantable Contraceptives. Curr Opin Obstet Gynecol. 1992;4(4):536-43. PubMed PMID: 1387011.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Injectable and implantable contraceptives. A1 - Cullins,V E, PY - 1992/8/1/pubmed PY - 1992/8/1/medline PY - 1992/8/1/entrez KW - Americas KW - Behavior KW - Contraception KW - Contraception Continuation KW - Contraceptive Agents KW - Contraceptive Agents, Female KW - Contraceptive Agents, Progestin KW - Contraceptive Implants KW - Contraceptive Methods KW - Contraceptive Usage KW - Depo-provera KW - Developed Countries KW - Drug Interactions KW - Drugs KW - Economic Factors KW - Family Planning KW - Injectables KW - Levonorgestrel KW - Literature Review KW - Medroxyprogesterone Acetate KW - Norethindrone KW - Norethindrone Enanthate KW - North America KW - Northern America KW - Psychological Factors KW - Research And Development KW - Satisfaction KW - Technology KW - Treatment KW - United States SP - 536 EP - 43 JF - Current opinion in obstetrics & gynecology JO - Curr Opin Obstet Gynecol VL - 4 IS - 4 N2 - In December 1990, the Food and Drug Administration approved Norplant (Wyeth-Ayerst, Radnor, PA) for general US use. This approval comes during a time period when the number of contraceptors relying on sterilization has risen, echoing known dissatisfaction with other reversible methods. During the past year, data have been presented that refute concern that Norplant may be an abortifacient. Continued estradiol production with development of follicles and ovulation in regularly menstruating women was documented. Ovulatory dysfunction among Norplant users, despite follicular development, was also detailed. Changes in carbohydrate metabolism were confirmed to be clinically insignificant. International development of biodegradable and non-biodegradable implants and 1, 3, or 6 months injectables continues. These injectable and implantable contraceptives promise diversity in contraceptive options to match diversity in contraceptive need and life style. SN - 1040-872X UR - https://www.unboundmedicine.com/medline/citation/1387011/Injectable_and_implantable_contraceptives_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=1387011.ui DB - PRIME DP - Unbound Medicine ER -